3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Mantle-Cell
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lymphoma
2
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Diseases
1
Interventions
Cytarabine
68
Cyclophosphamide
44
Methotrexate
41
Daunorubicin
38
Etoposide
34
Vincristine
30
Mercaptopurine
28
Dexamethasone
24
Radiotherapy
22
Idarubicin
22
Asparaginase
21
Thioguanine
20
Doxorubicin
19
Prednisone
17
Peripheral Blood Stem Cell Transplantation
17
Imatinib Mesylate
16
Busulfan
16
pegaspargase
15
Mitoxantrone
15
Filgrastim
13
Leucovorin
11
fludarabine phosphate
10
Hydrocortisone
10
nilotinib
9
Tretinoin
8
Prednisolone
8
Cyclosporine
8
Hydroxyurea
7
Epoetin Alfa
7
Azacitidine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia
×
acalabrutinib
×
Clear all
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA